Bictegravir + emtricitabine + tenofovir alafenamide

Bictegravir + emtricitabine + tenofovir alafenamide has been studied in 3 papers since 2024: 3 observational studies in people; 1 in the past year. The newest paper, Feb 20, 2026: “Changes in cardiovascular and metabolic risk scores after switching to DOR/3TC/TDF, DTG/3TC or BIC/FTC/TAF: results from a multicenter Italian cohort”.

Intervention

3 papers study it2 findingsUpdated

PubChemPubChemPubChemChEBIChEBIChEBI

See all 3 papers on bictegravir + emtricitabine + tenofovir alafenamide

At a glance

The findings reach people, from one lab or study. 1 lab in 1 country.

“and an increase of +0.3 with BIC ( P = 0.013)”
Changes in cardiovascular and metabolic risk scores after switching to DOR/3TC/TDF, DTG/3TC or BIC/FTC/TAF: results from a multicenter Italian cohortAIDS (London, England)2026doi:10.1097/qad.0000000000004468

None of its findings points the other way.

Humans: a single group. Cells, worms or flies and mice: nothing yet.
  • 1 lab in 1 country
  • Humans3

What did studies of bictegravir + emtricitabine + tenofovir alafenamide find?

2

Studies of bictegravir + emtricitabine + tenofovir alafenamide measured 2 outcomes: SCORE2 and METS-IR.

SCORE2

upin humans1

1 study
  1. Bictegravir + emtricitabine + tenofovir alafenamide is linked with higher SCORE2 in humans (people with HIV) (+0.30).

    Humanspeople with HIV48 weeks

More on SCORE2

METS-IR

upin humans1

1 study
  1. Bictegravir + emtricitabine + tenofovir alafenamide is linked with higher METS-IR in humans (people with HIV) (+0.3).

    Humanspeople with HIV48 weeks

More on METS-IR

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 1Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 01 paper in 12 months